drugset / Trial / NCT02489513

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

NCT02489513

Phase 1 Completed 8 enrolled Agios Pharmaceuticals, Inc.
NaSingle-groupOpen-label

Summary

The study is designed to characterize the absorption, metabolism, and excretion of AG-120 using radiolabeled drug in healthy adult male subjects to support its further development and registration.

Timeline

Start
2015-06
Primary completion
2015-09
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivosidenib Small molecule 500 mg Oral

Indications

No indication recorded.